InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,199.60
(
-0.34%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
-0.66%
)
Bitcoin
60,115.51
(
-2.43%
)
Post# of 23979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oldberkeley

Send PM Follow Ignore
Followers 58
Posts 5142
Boards Moderated 0
Alias Born 07/23/2007

oldberkeley

Re: LasNubes post# 6518

Friday, 04/17/2015 9:00:30 AM

Friday, April 17, 2015 9:00:30 AM

Post# of 23979
See the edit on my prior post, keep researching, just trying to help.

Good summary here:

http://www.fiercebiotech.com/story/athersys-tanks-its-stem-cell-therapy-flunks-phase-ii-stroke-trial/2015-04-17

From the article:

But management, as ever, sees a silver lining in the latest Phase II failure. Dicing up the data after the fact, Athersys notes that patients who got MultiStem earlier in the treatment window did better against the study's endpoints than those who got it later. That group consists of only 27 out of the 65 who got the stem cell treatment, however, and even those results failed to meet statistical significance.

All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up